Cardurion Pharma Stock

cardurion.comHealthcare / Healthcare softwareFounded: 2017Funding to Date: $866.77MM

Cardurion Pharmaceuticals is a biotechnology company that specializes in the discovery and development of therapies intended for cardiovascular disease. Cardurion Pharmaceuticals was founded in 2017 and is headquartered in Burlington, MA. Striving to address the unique needs of patients suffering from heart disease through novel approaches, the team manages the development and clinical trial stages for patients suffering from chronic heart failure along with related therapies that have broad potential for cardiovascular disease treatment.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Cardurion Pharma, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Cardurion Pharma Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Cardurion Pharma Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
07/16/2024 Series B $260.41MM $xx.xx $754.94MM Ascenta Capital, Bain Capital Life Sciences, Bain Capital Private Equity, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management & Research Company, Gv, Invus, Millennium Management, Nea
Price per Share
$xx.xx
Shares Outstanding
53,171,088
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascenta Capital, Bain Capital Life Sciences, Bain Capital Private Equity, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures, Farallon Capital Management, Fidelity Management & Research Company, Gv, Invus, Millennium Management, Nea
07/14/2023 Series A-5 $47.5MM $xx.xx $508.61MM Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
Price per Share
$xx.xx
Shares Outstanding
12,101,294
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
10/27/2021 Series A-4 $31.38MM $xx.xx $425.28MM Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
Price per Share
$xx.xx
Shares Outstanding
9,404,601
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
10/27/2021 Series A-3 $99.97MM $xx.xx $425.28MM Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
Price per Share
$xx.xx
Shares Outstanding
25,468,730
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bain Capital Life Sciences, Bain Capital Private Equity, Polaris Partners, Takeda Pharmeceuticals
11/20/2019 Series A-1 $46.12MM $xx.xx $157.83MM Polaris Partners
Price per Share
$xx.xx
Shares Outstanding
14,101,191
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Polaris Partners
03/20/2017 Series A-2 $14.46MM $xx.xx $72.28MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
5,198,934
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.3x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Cardurion Pharma Investors Also Invested in These Private Companies

Bain Capital Private Equity
Blue Owl Healthcare Opportunities
Takeda Pharmeceuticals
Takeda Pharmaceutical
Deepwork Capital

Leadership & Board

Leadership

Michael Mendelsohn MD
Founder
Peter Lawrence JD
Chief Executive Officer & President
Elizabeth Radcliffe
Chief Financial Officer
Marcia Moore
Chief Operating Officer
Howard Surks MD
Chief Medical and Scientific Officer & Head of Translational Medicine
Stephen Migausky
Chief Legal Officer

Board

Adam Koppel Ph.D
Bain Capital Life Sciences
Edward Mathers
New Enterprise Associates
Evan Rachlin MD
Ascenta Capital
Nicholas Downing MD
Bain Capital Life Sciences

Cardurion Pharma stock FAQs

plusminus

Can you buy Cardurion Pharma stock?

As Cardurion Pharma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Cardurion Pharma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Cardurion Pharma stock?

To invest in a private company like Cardurion Pharma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Cardurion Pharma stock?

Yes, you may sell the Cardurion Pharma stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Cardurion Pharma stock?

If you hold private company shares of Cardurion Pharma – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Cardurion Pharma on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Cardurion Pharma a public company?

No, Cardurion Pharma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Cardurion Pharma’s stock price?

Cardurion Pharma is a privately held company and therefore does not have a public stock price. However, you may access Cardurion Pharma private market stock price with Forge Data.
plusminus

What is Cardurion Pharma’s stock ticker symbol?

Cardurion Pharma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Cardurion Pharma News and Media Highlights

Cardurion Pharmaceuticals Announces $260 Million Series B Financing to Advance Its Pipeline of Innovative Medicines for Cardiovascular Diseases

In a series B funding round led by Ascenta Capital Cardurion raised $260 million.
Browse Insights
Updated on: Dec 14, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.